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1. Introduction  
1.1 Generation, role and destruction of reactive oxygen species 
Chronic kidney disease (CKD) is characterized by complex changes in cell metabolism 
leading to increased production of oxygen radicals which, in turn, may play a key role in 
numerous clinical complications of this pathological condition. Several reports have focused 
on the identification of biological elements involved in the development of systemic 
biochemical alterations in CKD (Granata et al., 2009). Under normal conditions in living 
organisms oxygen metabolism  (above all reduction) leads to the formation of highly 
reactive intermediates called reactive oxygen species (ROS) that are dangerous for the cell 
(Yu, 1994). As long as the balance between ROS production and ROS scavenging is 
maintained, no disorders are observed. ROS include superoxide anion (O2-), hydroxyl 
radical (OH), perhydroxyl radical (HO2) and singlet oxygen (1O2). According to some 
scientists,  hydrogen peroxide (H2O2) also belongs to this group since it easily penetrates the 
membranes and in the presence of transition metals (copper or iron) it can be reduced to 
OH as in the example below (Yu, 1994):  
 2
2 2H O  Cu  OH  OH    Cu+ ++ → + +──  
Hydroxyl radical is the strongest oxidant generated in biological systems because of its 
extremely short half-life (Yu, 1994; Fantel, 1996). Highly reactive hydroxyl radicals readily 
react with a variety of molecules. In general, the harmful effects of excess ROS on the cell  most 
often include damage of DNA, oxidation of polyunsaturated fatty acids (PUFA) in lipids (lipid 
peroxidation), oxidation of amino acids in proteins and oxidatively inactivate specific enzymes 
by oxidation of co-factors (Brenneisen et al., 2005; Valko et al., 2007). ROS form as a natural 
byproduct of the normal metabolism of oxygen and have important roles in cell signaling. 
However, during times of environmental stress (e.g., UV or heat exposure), ROS levels can 
increase dramatically, which may result in significant damage to cell structures. This 
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accumulates into a situation known as oxidative stress. ROS are also generated by exogenous 
sources such as ionizing radiation. In recent years, a substantial body of evidence has 
accumulated supporting a key role for ROS in many fundamental cellular reactions and 
suggesting that oxidative stress may be important in the pathophysiology of common diseases 
including atherosclerosis, malignant diseases, chronic kidney disease and diabetes mellitus as 
well as in the aging process (Young & Woodside, 2001; Sies, 1991).  
It has been shown that CKD patients are at substantially higher risk of cardiovascular 
diseases, atherosclerosis and cancer than age-matched subjects in the general population 
(Mandayam & Shahinian, 2008).  In CKD patients, the efficiency of the antioxidative defense 
system declines with the progress of the disease and reaches its peak in the end-stage. The 
extent of oxidative stress can be slowed by increased efficiency of the natural antioxidant 
system (Meydani, 2002). Mammalian cells are protected against ROS by two lines: 
endogenous mechanisms (mainly enzymes) and exogenous low molecular weight 
compounds (free radical scavengers) (Joseph, 1995). The antioxidant enzymes are: 
superoxide dismutases (SOD), catalases (CAT) and glutathione peroxidases (GSH-Px) and 
probably selenoprotein P (Joseph, 1995; Zachara et al., 2006). The share of these three 
enzymes that work closely together in ROS neutralization is shown in Fig. 1. 
SODs play a central role in catalyzing the spontaneous dismutation of superoxide producing 
O2 and H2O2. Marklund (1984) studied  SOD isoenzymes in human tissues and has shown 
that liver contains very little extracellular SOD and a lot of the other isoenzymes, whereas all 
isoenzymes are abundant in the kidney. Tissue homogenates from chronically rejected 
human renal allografts demonstrated decreased activity of MnSOD and increased 
expression of MnSOD protein (MacMillan-Crow et al., 1996). The molecular mechanisms 
involved in the induction of MnSOD during oxidative stress have yet to be elucidated.  
Protection by SOD is incompletely achieved if H2O2 is not subsequently degraded. H2O2 
accumulation, if not efficiently recycled, will lead to the appearance of the very aggressive 
OH. Decomposition of H2O2 is the function of CAT, which generates oxygen and water 
(Joseph, 1995). However in many cells CAT activity is very low, and frequently unavailable 
for H2O2 dismutation. Thus, in most tissues, the degradation of hydroperoxides is effected 
by GSH-Px. This enzyme contains essential trace element Se at the active site and reduces 
H2O2 to water and organic hydroperoxides to alcohols. Two forms of GSH-Px have been 
identified in blood: cellular, called cytosolic or classical (GSH-Px 1),  and extracellular 
(present in plasma; GSH-Px 3) (Arthur and Beckett, 1994). GSH-Px 3 is synthesized in the 
kidney and shows a significant diagnostic value in kidney diseases (Zachara et al., 2006).  
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Fig. 1. Antioxidant enzymes. All three enzymes are not localized in the same compartments 
of the cells: SODs are either in the cytosol (Cu-Zn SOD) or in mitochondria (Mn SOD); GSH-
Px is cytosolic; catalase is mainly found in peroxisomes (Adapted from Joseph, 1995). 
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Exogenous low molecular weight antioxidants include vitamins (A, C and E), carotenes, 
glutathione (GSH), uric acid, bilirubin and several trace elements (selenium, copper and 
zinc) (Young & Woodside, 2001, Joseph, 1995). The tripeptide GSH is generally considered 
an intracellular antioxidant and it plays a crucial role in the cells (Fantel, 1994). Being the 
most abundant antioxidant inside the cells, GSH can directly scavenge free radicals (OH, 
O2- and organic free radicals) (Yu, 1994) or act as a cosubstrate in the GSH-Px-catalyzed 
reduction of H2O2 and lipid hydroperoxides, a constituent of cell membranes (Loughrey et 
al., 1994; Zachara et al. 2005). Vitamin E is the most widely distributed antioxidant in nature. 
Among at least eight structural isomers of tocopherols, α-tocopherol is the best known  and 
possesses the most potent antioxidant activity. It is highly effective in providing protection 
against membrane lipid peroxidation by reacting with lipid peroxyl radicals (Yu, 1994). In 
patients with CKD vitamin E level is reduced and supplementation suppresses oxidative 
stress. Similarly, vitamin C may be effective in reducing complication events in HD patients 
(Del Vecchio et al., 2011). In maintenance HD patients, plasma malondialdehyde (MDA), 
which is the terminal compound of oxidation of PUFA, is elevated (Boaz et al., 1999; Paul et 
al., 1993; De Vecchi et al., 2009). Loguhrey et al. (1994) have shown that in the serum of CKD 
patients MDA level is 42% higher, and in patients on HD – 76% higher,  as compared with 
the control group. Hemodialysis did not change the elevated MDA concentration (Turi et al., 
1991), however it is notable that HD combined with Vitamin E supplementation to patients 
prevented the breakdown of PUFA and reduced MDA level (Roozbeh et al., 2011). Vitamin 
E supplementation to patients on HD resulted in progressive increase in red blood cell 
vitamin E and a concomitant progressive decrease in MDA concentration, suggesting  
associated diminution in oxidative stress. However, vitamin E supplementation did not 
affect some other protective mechanisms, namely GSH and SOD (Cristol et al., 1997).  
2. Selenium content and glutathione peroxidases activities in different stages 
of CKD 
Numerous studies suggest that the formation of trace elements-containing compounds 
(mostly enzymes) and not the elements per se are critical to biological activities. Trace 
elements, Se, Cu and Zn play an essential role in the antioxidant defense system. They 
perform antioxidative functions through proteins in which they are incorporated (El-
Bayoumy 2001). Se is a component of about 25 enzymes including the GSH-Px family, 
thioredoxin reductases and selenoprotein P which provide antioxidant protection against 
ROS-driven cancer initiation and promotion, as well as some others (Zachara et al., 2006; 
Brozmanova et al., 2010). The other two elements, Zn and Cu are incorporated inter alia into 
SOD. Cu is also a component of several other enzymes, for example, ceruloplasmine and 
cytochrome oxidase (L’Abbe and Friel, 1992). Cu deficiency leads to increased generation of 
free radicals and can promote lipid peroxidation (Lai et al., 1996). Zn is incorporated into 
many proteins, of which several hundred are enzymes (Valee, 2001). All mentioned 
enzymes participate in the metabolism of nucleic acids, proteins, carbohydrates and others. 
In a healthy person the kidneys play an important role in the homeostasis of several trace 
elements, including Se (Wasowicz and Zachara, 1987). When Se is consumed at rates close to 
the human nutritional requirement, its highest levels are found in the kidneys and followed 
by the liver (Lockitch, 1989; Zachara et al., 2001c; Zachara et al., 2006). The Se level in tissues 
depends on its daily intake and the ingested chemical form. In people living in seleniferous 
regions the level is much higher than in those living in low Se areas e.g. New Zealand and 
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the Keshan region in China (Casey et al., 1982; Yang et al., 1989). Se is excreted from the 
organism mainly in the urine and feces, but urine contains 50-70% of the ingested element 
(Sanz Alaejos and Diaz Romero, 1993). Some authors (Yang et al.,1989) studied the relation 
between Se intake and urinary Se excretion in Chinese people living in different regions 
(low and high Se levels in the soil) and found a linear, significant correlation (r = 0.886; P < 
0.001) between these two parameters. The amount of urine Se excretion increased 
progressively with increasing Se intake, but the form in which selenium was excreted in the 
urine remained unknown for a long time.  
It was thought that the main form of Se excreted with urine is the metabolite called 
trimethylselenonium ion (TMSe) (Byard, 1969; Suzuki, 2005). In fact, this compound was 
isolated from  rat urine and it represented 20-50% of Se excreted (Palmer et al.1970). Later on 
TMSe was identified in human urine (Francesconi and Pannier, 2004). Recent analytical 
advances based on HPLC separations coupled with atomic and molecular mass 
spectrometric detection have provided new insights into this area. New Se-containing 
carbohydrates (selenoshugars) are now known to be the major urinary metabolites in 
humans and in rats. The major metabolite is beta-methylseleno-N-acetyl-D-galactosamine 
(Suzuki et al, 2005). This selenosugar plateaus with a dose higher than 2.0 µg Se/mL water 
or g diet, and TMSe starts to increase in higher Se intakes, indicating that TMSe can be a 
biomarker of excessive and toxic doses of Se. TMSe is now considered to be a less significant 
metabolite (Francesconi, 2006). More recently it has been shown that after Se 
supplementation to mice the element is metabolized mainly in the liver and kidney (Suzuki 
et al, 2010). Excess Se was associated with selenosugar in the liver, transported to the kidney 
and the excess amount was excreted mainly as a selenosugar in urine. Quite recently French 
authors have identified, for the first time, a novel Se metabolite in human urine – Se-
methylselenoneine (Klein et al., 2011). It cannot be ruled out that the use of other methods of 
analysis will discover more selenium compounds in urine. 
2.1 Selenium concentration in the blood components of chronic kidney disease 
patients 
Free radicals damage different tissues or organs, hence the trace and toxic elements behave 
differently in various organs. Available data suggested that in patients with CKD the levels 
of cadmium, chromium, copper, lead and vanadium are higher and the levels of selenium, 
zinc and manganese are lower than in healthy subjects (Tonelli et al., 2009). Among various 
important elements in CKD patients, Se is the focus of this study, therefore  attention will be 
concentrated on this element and on GSH-Pxs present in blood.  
Although some authors did not find any differences between Se concentration in the blood 
components between CKD patients and controls (Milly et al., 1992) many others found 
significantly lower values (for a review see Zachara et al., 2006). Several authors have shown 
a gradual decrease of Se level along with the progress of the diseases (Ceballos-Picot et al., 
1996; Zachara et al., 2004). An example is shown in Fig. 2 (taken from Zachara et al., 2004a). 
Several authors have shown that in non-dialyzed CKD patients the overall plasma Se 
concentration from incipient to the end stage of the disease is 12.5 to 44% lower than in healthy 
subjects (Ceballos-Picot et al., 1996; Richard et al., 1991; Zachara et at., 2001a). It has been 
shown that in the early stage of CKD, Se concentration in whole blood and plasma does not 
differ significantly from the values found in the control group (Ceballos-Picot et al., 1996; 
Zachara et al., 2001b). Along with the progression of the kidney impairment, Se concentration 
decreases in whole blood and plasma. This was particularly evident in the end-stage of the 
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disease, where Se concentration in whole blood and plasma was lower by 47 and 50%, 
respectively (P < 0.0001) as compared with the control group (Zachara et al., 2000b).  
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Fig. 2. Selenium concentration in plasma in controls and in different stages of CKD patients; 
( p < 0.01;  p < 0.001  vs ctr.)∗ ∗∗ . 
Methods of assessing the degree of renal damage in these patients include serum 
creatinine level, creatinine clearance and glomerular filtration rate (Krol and Rutkowski, 
2008). The data presented in this paper are based mainly on the concentration of 
creatinine in plasma. Creatinine levels in CKD patients increase gradually with the 
development of the disease. Generally in CKD patients the concentration is several times 
higher than in healthy subjects (Zachara et al., 2004b; Rohun et al., 2011) and is highest in 
ESKD patients. In HD and in peritoneal dialysis patients the concentration is even higher 
(Zagrodzki et al. 2007; Mekki et al., 2010). Hemodialysis usually does not change the 
elevated concentration of creatinine (Mekki et al., 2010). Zachara et al. (2004a) have 
shown, in the entire group of CKD patients, a significant negative correlations between 
plasma selenium and plasma creatinine levels (r = –0.380; P < 0.0001; Fig. 3).  
 
Creatinine concn in plasma (mg/dL)  
Fig. 3. Correlation between plasma selenium and ceatinine concentrations in control group 
and in different stages of chronic kidney disease patients (taken from Zachara et al., 2004a). 
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Schiavon et al. (1994a) studied 34 patients with different degrees of renal impairment, and 
found higher negative correlation between plasma selenium concentration and serum 
creatinine values (r =-0.55; P < 0.001). A negative correlation between Se concentration in 
plasma and creatinine clearance (r =-0.47, P < 0.001) was found by Ceballos-Picot et al. 
(1996). Ceballos-Picot et al. (1996) have shown that plasma Se concentration in patients on 
HD was more than 50% lower as compared with patients in advanced stage of the disease. 
However, many other authors found that the degree of Se reduction  in dialyzed patients 
was similar to that observed in non-dialyzed patients who are in more advanced stages of 
the disease (for details see Zachara et al., 2006). 
The biological significance of low Se concentrations in the blood is not fully understood, 
but severe deficiency leads to cardiomyopathy, as for example in the Keshan region in 
China (Ge et al., 1983). Lower concentrations of serum Se without severe deficiency have 
been associated with hypertension, heart disease and coronary disease in the general 
population, and with cardiomyopathy among dialysis patients. Mild Se deficiency 
appears to increase the susceptibility to oxidant stress, which may be relevant to 
hemodialysis patients in whom oxidative stress is markedly increased (Tonelli et al., 
2009). 
The question arises as to the cause of the low concentration of selenium in patients with 
CKD. Se levels in blood components are influenced by diet and food intakes, which are the 
principal source of this element. The lower Se levels in whole blood and plasma in uremic 
patients can be associated with the decreased intake of protein and increased protein loss 
with urine. Usually the patients are advised to consume limited amounts of protein to 
relieve uremic symptoms and to decrease the progression of kidney function (De Luis and 
Bustamante, 2008). Protein is the main source of Se, therefore the quantity of the element 
supplied is reduced (De Luis and Bustamante, 2008). Marchante-Gayon et al. (1996) 
indicated that the majority of Se (about 95%) seems to be bound to serum proteins. The most 
abundant selenoproteins in the blood components are selenoprotein P and GSH-Px (Ashton 
et al., 2009). Deagen et al. (1993) have shown that the Se is incorporated, in the form of 
selenocysteine (Sec), to selenoprotein P (≈ 50% of plasma selenium) and GSH-Px (which 
accounts for 10-30% of plasma selenium) or bound in the form of selenomethionine to 
albumin (≈ 23%). Very similar results have been obtained for blood plasma in healthy 
subjects by Koyama et al. (1999). They have shown a preference for supplemented Se to be 
taken up as selenoprotein P, the protein that incorporates up to 10 selenocysteine residues 
into the polypeptide chain (Persson-Moschos et al., 1995).  
In CKD patients protein, and especially albumin concentration in plasma is lower than in 
healthy subjects (Dworkin et al., 1987; Zachara et al., 2004b; Zima et al., 1998). The precise 
cause remains unknown, but it is believed that among others the restricted diet, urinary or 
dialytic losses, impaired intestinal absorption, abnormal binding to Se transport proteins or 
drug therapy may all be responsible (Olson and Palmer, 1999; Vendrely et al., 2003; 
Bonomini and Albertazzi, 1995; Lockitch, 1989; Pasaoglu et al., 1996). Since protein 
foodstuffs contain the largest amount of Se, reduced protein intake seems to be a substantial 
cause of low Se concentration (Bonomini and Albertazzi, 1995). A strong positive correlation 
was noted between plasma total protein and albumin and Se concentration in healthy 
subjects and CKD patients (Dworkin et al., 1987; Zachara et al. 2004b). The results of my 
group are presented in Fig. 4.  
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Fig. 4. The relationship between plasma total protein (A) and albumin (B) levels and plasma 
selenium concentrations in the control group (▲) and in patients at different stages of CKD 
patients () (taken from Zachara et al., 2004b). 
3. Glutathione peroxidase activities in the blood of patients in different 
stages of chronic kidney disease and on hemodialysis 
In human tissues, among about 25 selenoproteins (Papp et al., 2007), five  are glutathione 
peroxidases: cytosolic (cellular, classical), (GSH-Px 1), gastrointestinal (GSH-Px 2), plasma 
(extracellular) (GSH-Px 3), phospholipid (GSH-Px 4) and sperm nuclei (GSH-Px 5) (Behne 
and Kyriakopoulos, 2001; Brigelius-Flohe, 2006). All of them can metabolize hydrogen 
peroxide and organic hydroxides (Arthur, 2000). Two of GSH-Pxs are present in the blood: 
GSH-Px 1 present in red blood cells and GSH-Px 3 present in plasma. Both have a tetrameric 
form and contain one selenium per subunit (or four gram atoms of Se per mole of enzyme) 
in the form of Sec (Maddipati and Marnett, 1987, Zachara, 1992). Se supply has been shown 
to induce the synthesis of these enzymes (Beilstein and Whanger, 1986). The relative 
position of the selenoproteins within the hierarchy is believed to reflect the relative 
biological importance. In the GSH-Pxs family the two extremes are represented by GSH-Px 1 
and GSH-Px 3, which disappear rapidly in even moderate Se deficiency (Brigelius-Flohe, 
2006).  
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Cellular GSH-Px is present in all tissues, and was detected by Mills (1957) as an enzyme 
involved in the protection of red blood cells against oxidative hemolysis. It was the first 
protein with selenium in the polypeptide chain to be identified independently by Flohe et 
al., (1973) and Rotruck et al. (1973). Plasma GSH-Px was recognized as a distinct from the 
red cell enzyme. Later on it was purified and characterized from human plasma (Broderick 
et al., 1987). This enzyme is structurally, enzymatically and antigenically different from that 
in erythrocytes and other cells (Zachara, 1992). GSH-Px 3 is widely used as the marker of Se 
status (Papp et al., 2007). 
Studies on red blood cell GSH-Px activity in CKD patients produced  inconsistent results.  
Some authors found significantly lower (Zachara et al., 2001a; 2004a; Bulucu et al., 2000; 
Martin-Mateo et al., 1999), some - significantly higher (Ceballos-Picot et al., 1996; Mimic-Oka 
et al., 1992) and still others did not observe any differences (Zachara et al., 2004b; Temple et 
al., 2000). It can be concluded that bone marrow in CKD patients is not damaged and the 
synthesis of this enzyme does not deviate from the norm. In patients on dialysis the activity 
of this enzyme is similar as in ESKD (Ceballos-Picot et al., 1996).  
In CKD patients plasma GSH-Px seem to be much more important than red cell  enzyme. 
Therefore it is worthwhile to concentrate primarily on  plasma GSH-Px in CKD patients. 
Studies on this enzyme have shown that although GSH-Px 3 is synthesized in a range of 
tissues, the renal proximal tubular epithelial cells are the main source from which it is 
secreted into plasma (Avissar et al., 1994; Whitin et al., 1998). Many reports indicate that 
patients with CKD have very low plasma GSH-Px activity (Yoshimura et al., 1996, Zachara 
et al., 2004a, Ceballos-Picot et al., 1996) including those undergoing HD (Yoshimura et al., 
1996, Roxborough et al., 1999, Ceballos-Picot et al., 1996, Zachara et al., 2001a). Reports by 
several authors have shown that plasma GSH-Px activity in uremic patients is reduced by 
34-52% as compared with healthy controls (Richard et al., 1991; Schiavon et al., 1994a; 
Ceballos-Picot et al., 1996; Yoshimura et al., 1996;  Zachara et al. 2004a). Some of the authors 
indicated a gradual decrease in the activity with advancing stage of the disease. An example 
is shown in Fig. 5 B (Zachara et al., 2004a). 
 
 
Fig. 5. Glutathione peroxidase activity in red blood cells (A) and plasma (B) in the control 
group and in patients with chronic kidney disease (CKD) in various stages of the disease. 
Patients were divided according to plasma creatinine (cr.) level: group I, incipient (n = 55) 
with cr. up to 1.36 mg/dL; group II, moderate (n = 40) with mean cr. level 1.72 mg/dL; 
group III, advanced (n = 40) with mean cr. level 3.96 mg/dL; group IV, end stage (n = 15) 
with mean cr. level 4.87 mg/dL. Statistics: *, P < 0.01 vs. control; **, P < 0.0001 vs. control 
(Adapted from Zachara et al., 2004b). 
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In contrast to the concentration of selenium, which does not differ in the initial stage of the 
disease from healthy subjects, the activity of GSH-Px already in the incipient stage was 
significantly lower (P < 0.0001) than in the control group. In the end stage of CKD, the 
activity of this enzyme decreased to one third of the value observed in the healthy subjects. 
A negative, statistically significant, correlation between plasma GSH-Px activity and 
creatinine concentration (r = -0.657) as well as between plasma GSH-Px activity and urea 
nitrogen (r = -0.653) in plasma was revealed (in both parameters P < 0.0001) (Fig. 6). A 
progressive decline in the activity of this enzyme is linked with the fact that GSH-Px 3 is 
primarily synthesized in the kidney and the progressing damage of this organ is reflected in 
diminished enzyme activity. Low GSH-Px 3 activity found in ESKD may depend on its 
synthesis in the residual, non damaged cells of the kidney and in other tissues/organs that 
synthesize small amounts of this enzyme. It has been shown that in humans this peroxidase 
is synthesized also in the liver, heart, lung and breast (Chu et al., 1992).  
 
 
 
Fig. 6. Relation between plasma GSH-Px activity and creatinine level in CKD patients (taken 
from Zachara et al., 2004b). 
4. The effect of selenium supplementation to CKD and HD patients  on 
plasma GSH-Px activity and protein level 
In healthy persons, Se supplementation leads to increased GSH-Px activity in red blood 
cells, plasma, other body fluids and tissues (Trafikowska et al., 1998; Iwanier and Zachara, 
1995; Zachara et al., 1993). In plasma it reaches plateau value after 3-4 weeks of 
supplementation (Trafikowska et al., 1998; Iwanier and Zachara, 1995; Bonomini et al., 
1995). In red blood cells, after Se supplementation, the GSH-Px activity increases much more 
slowly than in plasma (Trafikowska et al., 1998; Iwanier and Zachara, 1995) because of long 
life span of these cells. Thus plasma GSH-Px activity is a more sensitive index of short-term 
Se status, whereas red cell GSH-Px activity gives a long-term index status (Thomson and 
Robinson, 1980).  
There is a dearth of publications on the effect of Se supplementation to CKD patients. Saint-
Georges et al. (1989) were probably the first to supplement uremic, hemodialyzed patients 
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with sodium selenite administered orally. After supplementation (3 months with 500 µg/day 
and then for 3 months with 200 µg/day) plasma GSH-Px activity increased to a plateau after 
16 weeks but remained about 30% lower than the control values. Studies of the effects of Se 
supply on plasma GSH-Px activity in patients on HD, carried out by various authors, have 
produced ambiguous results. Some authors show statistically significant increase in this 
enzyme activity after Se supplementation to dialyzed patients (Richard et al., 1991; Richard et 
al., 1993; Bellisola et al., 1994), others have shown slightly raised activity at the end of the HD 
session (Schiavon et. al., 1994a) or did not report any substantial differences (Zachara et al., 
1994, 2001). Zachara et al. (2004b) supplemented CKD patients with Se in the incipient stage of 
CKD and in the end stage and have shown that in patients in the initial stage of uremia Se 
supplementation enhances plasma GSH-Px activity, whereas in the more advanced stages, the 
increase is much lower or does not occur at all.  Schiavon et al. (1994a, 1994b) suggest that the 
measurement of plasma GSH-Px activity in CKD patients should be complemented by the 
determination of serum creatinine level and creatinine clearance, and may have a considerable 
diagnostic value, which means that this enzyme may be regarded as an additional marker 
useful in assessing the extent of CRF progress. 
Yet there is no conclusive evidence whether CKD patients show a lowered plasma GSH-Px 
activity, or decreased synthesis of this enzyme. It is thought that  endogenous, toxic 
compounds in the blood, which exert an  inhibitory effect on this enzyme, are responsible 
for the decrease in GSH-Px activity. During dialysis, these compounds are removed so that 
the enzyme activity is enhanced. To explain whether this group of patients demonstrates a 
decrease in peroxidase activity or its synthesis, Yoshimura et al. (1996) determined 
simultaneously plasma activity and protein GSH-Px concentration in several non-dialyzed 
patients. In the study group, the enzyme activity was  over 50% lower than in controls, and 
plasma concentration of GSH-Px protein was reduced or undetectable. The authors 
conclude that the decreased plasma activity of this enzyme in CKD patients was associated 
with its low concentration. The data reported by them (Yoshimura et al., 1996) show that the 
lowered plasma concentration of GSH-Px protein may be attributed to impaired 
biosynthesis of this enzyme in the kidney. The authors made other interesting observations. 
Since it had previously been thought that the decreased plasma GSH-Px activity in CKD 
patients may result from Se deficiency (Richard et al., 1991), they determined Se 
concentration in plasma and GSH-Px activity in red blood cells, and observed normal Se 
concentration and higher GSH-Px activity in red blood cells in patients than in the control 
group. The conclusion was that the lowered plasma GSH-Px activity cannot be attributed to 
blood Se deficiency. With regard to the concentration of GSH-Px protein, Roxborough et al. 
(1999) presented results completely opposite to those reported by Yoshimura et al. (1996). 
They obtained specific antibodies against GSH-Px of human plasma and determined plasma 
concentration of GSH-Px protein in the control group and in patients on dialysis. The 
significant findings were as follows: enzyme activity in patients before dialysis was over 
50% lower than  in healthy persons and it increased significantly after dialysis, but did not 
reach the value observed in the control group; secondly, before and after dialysis, plasma 
concentration of GSH-Px protein was at the same level, and,  even more importantly, it did 
not differ from that observed in healthy persons.  
Zachara et al. (2009) supplemented 30 patients on HD for 3 months with 200 µg Se/day 
(yeast Se) and have shown that plasma element concentration increased from 42 ng/mL (0 
day) to 102 and 132 ng/mL after 1 and 3 months, respectively (P < 0.0001), but plasma GSH-
Px protein level did not change significantly and was 11.4 µg/mL at the beginning (4.2 times 
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lower as compared with the control group – 48.4 µg/mL) and 11.8 µg/mL after 3 months. 
This level was similar to the group on placebo. These data show that Se supply to CKD 
patients on HD has no effect on the level of plasma GSH-Px protein (Fig. 7).  
 
 
Fig. 7. Plasma GSH-Px protein level in healthy subjects and in CKD patients on HD 
supplemented with selenium and placebo. CKD patients on hemodialysis at the beginning 
of the study (HD 0) and after 1 and 3 months (HD 1 and HD 3, respectively) of Se or placebo 
supplementation. HD patients: white columns = placebo, black columns = + Se. Statistics: a, 
P < 0.0001 vs. controls (taken from Zachara et al., 2009). 
Our results on the effect of Se supplementation to HD patients on GSH-Px protein level are 
the first published to date. Thus the question of the effect of Se on GSH-Px level in HD 
patients remains open and the matter requires further study. 
5. Antioxidants in patients after kidney transplantation and the effect of Se 
supplementation 
Kidney transplantation is one of the ways of kidney replacement therapy. Currently, kidney 
transplantation is the treatment of choice in patients with ESKD, showing higher survival rates 
than dialysis (Luque Galves et al., 2005). Kidney transplantation is now the only treatment that 
may restore plasma GSH-Px in patients suffering from ESKD. Data on Se concentration and 
GSH-Px activities, and some other parameters, in blood of patients after kidney 
transplantation is still rather scarce. To the best of my knowledge there were, except ours, two 
research centers reporting the results on the antioxidant status in patients in early stages after 
kidney transplantation: one in the United States (Avissar et al., 1994; Whitin et al., 1998) and 
one in Spain (De Vega et al., 2002; 2003). In this article I will focus on the GSH-Px.  
In 1990 Avissar et al. (1994), searching for the source of plasma GSH-Px, studied the activity 
of this enzyme in the serum and plasma of anephric patients (cf. Zachara et al., 2006). They 
found that the activity was 22.6% of that noted in matched controls and was also 
significantly lower than plasma GSH-Px activity in HD patients. The authors also examined 
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GSH-Px activity and Se concentration in plasma of HD patients and controls. The patients' 
plasma Se levels were within the normal range, while GSH-Px activity of HD patients was 
42% of the activity of the control group (P < 0.001). In this way the authors proved that the 
reduction in plasma GSH-Px activity could not be attributed to the lowered Se 
concentrations because: 1) the Se level in the patients’ plasma was not significantly different 
from that in the controls; 2) when the patients were divided into two subgroups by Se levels 
(with the level below 96 ng/mL, and higher than 138 ng/mL), there was no significant 
difference in their plasma GSH-Px activity, and 3) the patients showed high (142% of the 
control value) red blood cell GSH-Px activity. In the sera of patients who had undergone 
transplantation, Se levels and GSH-Px activities were measured 22 and 30 days after 
surgery. Se level was the same as before transplantation, while  plasma GSH-Px activity was 
eight times higher than before surgery and two times higher than in the controls. Several 
months after transplantation, plasma GSH-Px activity returned to normal values of healthy 
persons. Whitin et al. (1998), from the same center, transplanted kidneys in three groups of 
patients: 1) sixteen adults with renal disease who received a kidney transplant from related 
donors; 2) six adult patients who received cadaveric kidney transplants; and 3) three 
pediatric patients undergoing bilateral nephrectomy with subsequent kidney 
transplantation from related donors (cf., Zachara et al., 2006). Before transplantation, the HD 
patients had  plasma GSH-Px activity of 34% (group 1) and 50% (group 2) of the control 
plasma, while the anephric individuals (group 3) had  plasma GSH-Px activity ranging from 
2 to 24% of that recorded in controls. After transplantation, plasma GSH-Px activity 
increased very rapidly: in group 1, the enzyme activity was two times higher three days 
after transplantation than before the operation, and 21 days post-transplant the averaged 
activities were within the normal values. In group 2, plasma GSH-Px activity increased 
rapidly over the first two weeks post kidney transplant. In six patients of this group, plasma 
GSH-Px activity reached normal levels after 9.8 days, and 27 days post-transplant the 
plasma enzyme activity reached a maximum level – 144% of the control value. The 
maximum level was temporary and after several weeks it decreased to a range similar to 
that of healthy individuals.  
Our group studied the status of some antioxidants in the blood of patients before and in 
the early stages after kidney transplantation. I will focus my attention on some of the 
antioxidant parameters studied by us, namely on Se concentrations, red cell and plasma 
GSH-Px activities and some other parameters (Wlodarczyk et al., 2003). We found that 
whole blood and plasma Se concentration in patients before transplantation (79.2 and 64.3 
ng/mL, respectively) was significantly lower as compared with healthy subjects (93.5 and 
78.8 ng/mL, respectively; P < 0.001). The element concentration decreased significantly 
both in whole blood and in plasma (P < 0.05) within a week period after transplantation 
but returned to the values of the control group after 30 days. In the next two months there 
was a further, slight increase in Se concentration. Morris-Stiff et al. (2005) have shown that 
in 30, out of 40 patients before transplantation Se level in plasma was lower than in 
healthy subjects, but this was normalized in the majority of patients within 3 months. A 
decrease of Se in the first few days after surgery in our study is very likely associated with 
the restricted protein intake (the main source of Se) just after surgery. During the first 36-
48 h after surgery, the patients received only fluids containing no protein or selenium. 
From the second/third day, a diet containing protein was introduced, so that the Se level 
increased slowly. GSH-Px activity in the red cells of patients before transplantation 
(15.3±3.6 U/g Hb) was the same as in controls (16.3±2.7 U/g Hb) and did not change 
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during the entire period of the study (it ranged from 15.3 to 16.3 U/g Hb). However, 
plasma GSH-Px activity of patients before surgery (76.7±20.6 U/L) was lower by 61% as 
compared with healthy controls (196±23.4 U/L p<0.0001). After transplantation,  plasma 
GSH-Px activity increased very rapidly: by 53% after 3 days (p<0.0001), 90% after 7 days, 
and 2 weeks following surgery it almost reached  the value of the control group (177 
U/L). Two weeks later (at day 30 after transplantation) the activity exceeded the value of 
the control group. This higher activity was temporary and, similar to Whitin's study 
(1998), after several months it decreased to a range similar to that of healthy controls (Fig. 
8).  
Our results for the rapid increase in GSH-Px activity in plasma after kidney transplantation 
are in accord with the data of Whitin et al. (1998) who found that at 21 days post-transplant, 
the averaged plasma GSH-Px activity reached the normal value. De Vega et al. (2002, 2003) 
have shown that before transplantation plasma GSH-Px activity was – similar to our study – 
significantly lower than in the controls. The surprising  results of these authors were  that 48 
hours following transplantation  plasma GSH-Px activity decreased by 11% as compared to 
the pre-transplant value, whereas 7 and 14 days after surgery the enzyme activity increased 
by only 11 and 17% as compared to the initial value (P > 0.05). The cause of the decreased 
GSH-Px activity two days after transplantation and the very slow increase at a later stage 
remains unclear and open to speculation. 
The plasma creatinine level, which in patients before surgery (6.93±2.29 mg/dL) was 
significantly higher (p<0.0001) than in the control group (0.8±0.1 mg/dL), decreased during 
the study and after 3 months it was 1.57 mg/dL. These data (plasma GSH-Px activity and 
creatinine concentration) indicate that the transplanted kidney takes up its function very 
rapidly. A highly significant negative correlation was found between creatinine level and 
plasma GSH-Px activity (r = -0.588, p<0.001).   
According to my knowledge there are only few reports dealing with antioxidants in the 
blood of patients several months – several years following kidney transplantation. Simic-
Ogrizovic et al. (1998) have shown that in recipients with stable kidney function 5 years 
post-transplant, plasma GSH-Px activity was the same as in the controls but in patients 
with chronic rejection, the enzyme activity  was still significantly lower. Juskowa et al. 
(2001), studying the red cell GSH-Px activity several years after transplantation, found 
normal or decreased activity of this enzyme, depending of the medical treatment. Turan et 
al. (1992) studied, among other antioxidants, plasma GSH-Px activity in 30 kidney 
transplants 5 – 53 months (mean 19.9) after transplantation and found that the activity 
was significantly (P < 0.001) lower as compared with healthy individuals (3.40 vs. 10.43 
U/L). Cristol et al. (1998) studied two similar groups of patients more than one year after 
transplantation and showed that in both groups plasma GSH-Px protein level was higher 
as compared with controls, but in the group with no clinical signs of chronic rejection the 
enzyme protein level was higher by 60% as compared with the group of histologically 
proven chronic rejection. Our results on rapid increase in plasma GSH-Px activity in post-
transplant patients and the data on increased synthesis of plasma GSH-Px protein 
(Zachara et al., 2005, 2009) clearly show that the decreased plasma GSH-Px activity is 
most probably a consequence of impaired synthesis of this enzyme in the kidney. A 
significant negative correlation between plasma GSH-Px activity and creatinine 
concentration found in our study also support this supposition. 
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Fig. 8. Plasma GSH-Px activity in patients with ESKD before and after kidney 
transplantation and in healthy subjects. Please note a very rapid increase in the activity of 
this enzyme (taken from Wlodarczyk et al., 2003). 
In a number of our patients hemodialysis was introduced  almost immediately after surgery 
(Zachara et al., 2004c)  because of the absence of  kidney function. There were 15 men and 15 
women aged 26-67 yrs (mean = 47.6 ± 11.3 yrs). The patients received grafts from 1 related 
living donor, and 29 kidneys from cadavers.  All of them received the allografts for the first 
time. The mean serum creatinine concentration of patients was 7.72±2.35 mg/dl. The control 
group comprised 20 healthy volunteers (mean age, 43.0 ± 9.92 yr). It is interesting  that in the 
group of patients who underwent two or more dialyses during the study, in the third day 
after transplantation (group 1; n = 19) plasma GSH-Px activity was significantly lower (P < 
0.02) than in the group which only had  one or did not require dialysis at all (group 2; n = 
11). We examined those patients up to three months following surgery and the activity of 
this enzyme in the dialyzed group, during the entire period, was significantly lower (0.05 < 
P < 0.01) as compared with group 2 (Fig. 9, left part). On the contrary, creatinine 
concentration in group 1, from 3 to 30 days after transplantation, was significantly lower 
(0.0001 < P < 0.01) than in group 2. (Fig. 9, right part).  
When calculating the relationship between plasma GSH-Px activity and creatinine level in 
the entire period of the study, we found a highly significance negative correlation (r = -650; 
P < 0.0001). This correlation was lower in subgroup 1 (r= -472; P < 0.001) and higher in 
subgroup 2 (r= -0.676; P < 0.0001).  
While at present we have no convincing explanation for these disparate results, one can 
suspect that the main factor could be the immediate or delayed function of the transplanted 
kidney. In patients with immediate graft function and subsequent plasma creatinine level 
decline, plasma GSH-Px activity increases relatively fast and reaches the levels for healthy 
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subjects very soon after operation. On the other hand, when delayed graft function is noted, 
the increase in GSH-Px activity is much slower, as shown by different correlation factors 
between these two groups. A satisfactory explanation of this situation will require further 
studies.  
The amount of Se in the diet in Poland and in some European countries is low and, 
consequently, the dietary element intake is below the recommended value. Diet is the main 
source of selenium  and approximately 80% of dietary Se is absorbed depending on the type 
of food consumed (Navarro-Alarcon & Cabrera-Vique, 2008). Patients with CKD are advised 
to consume limited amounts of protein (the main source of Se). Thus, patients with ESKD 
have low Se levels in the blood. That is why our group wanted to check the effect of Se 
administration on blood GSH-Px activity in patients after kidney transplantation 
(Wlodarczyk et al., 2005).  
To my knowledge there is only one publication on the effect of Se supplementation to 
patients after organ transplantation (Bost  & Blouin, 2009). The authors have shown that in 
the plasma of patients before kidney and heart transplantation (month 0) Se levels were 
similar (94 and 96 µg/mL). The authors studied the effect of Se (as yeast-Se) 
supplementation on plasma element concentration in patients of kidney and heart recipients 
over a period of  3 years. They found that recipients who were supplied with 200 µg Se/day, 
after 12 and 24 months after surgery had the same level of Se in plasma (176 µg/L), and after 
36 months the level was almost the same (182 µg/L plasma). This means that in those 
patients Se level reached a plateau after 12 months and was 1.9 times higher than at month 0 
(P < 0.0001).  
 
 
Fig. 9. (left part): Plasma GSH-Px activities before and after kidney transplantation in 
patients, who after surgery were not dialyzed (columns on the right) and those who had 2 – 
11 HD sessions. Statistics between groups: a, P < 0.02; b, P < 0.01; c, P < 0.05. (right part): 
Creatinine levels in the same patients. Statistics between groups: a, P < 0.01; b, P < 0.0001. 
Our study comprised thirty two patients: 17 were supplied with 200 µg Se/day (yeast-rich 
Se) and 15 patients were administered placebo. The study lasted 3 months. The data on 
plasma Se concentration and plasma GSH-Px activity are shown in Fig. 10. In the placebo 
group plasma Se concentration increased gradually from the 7th day and at day 90 it almost 
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reached  the value of the control group, while in Se supplemented group at day 14 the level 
was the same as in controls and at day 90 it was higher than in controls by 39.0% (P < 
0.0001). Kidney transplantation or Se supplementation to patients following surgery had no 
influence on red cell GSH-Px activity. During the entire period, in both groups (yeast-Se and 
placebo), this activity ranged from 14.5 to 15.7 U/g Hb and did not differ from the control 
group (16.7 U/g Hb; data not shown). In plasma, however, GSH-Px activity increased 
gradually in both groups, but after 30 and 90 days after transplantation in the Se supplied 
group the activity was significantly higher as compared to the placebo group. Se 
supplementation induces the synthesis of plasma GSH-Px in the transplanted kidney and, 
very likely,  also in other tissues. It can thus be concluded that Se supplementation to kidney 
recipients has a positive effect on plasma GSH-Px activity and may be advisable in 
individuals affected with moderate impairment of kidney function. 
6. The effect of selenium supplementation in hemodialyzed patients on the 
prevention of DNA damage in white blood cells 
As stated in the introduction, oxidative stress, described as a disturbance in the prooxidant-
antioxidant balance in favor of the former, leads to oxidative damage. It induces DNA 
damage, lipid peroxidation of PUFA in cell membranes, protein modification and others. 
Such effects are observed in CKD patients, especially in ESKD and in patients on HD. In 
those patients numerous diseases, such as cancer, cardiovascular complications, diabetes, 
atherosclerosis and neurological disorders are more frequent than in the age-matched 
subjects in the general population (Himmelfarb & Hakim, 2003). Many publications have 
shown that in patients undergoing HD some plasma antioxidant enzymes (mainly GSH-Px) 
activities are significantly lower (Zachara et al., 2000; Zachara et al., 2006; Yoshimura et al., 
1996; Guo et al., 2009; Zwolinska et al., 2006). These enzymes, along with other antioxidants, 
protect the organism against ROS. ROS attack on DNA generates several modified DNA 
bases. The presence of these bases in cells may lead to mutagenesis. Such effects are 
observed in CKD patients, especially in ESKD and in patients on HD. Iseki et al. (1993) and 
Vamvakas et al. (1998) have shown that at the end-stage of CKD, the incidence of 
malignancies is higher than in the general population.. Kuroda et al. (1988) showed that in 
patients with diagnosed cancer of different sites (larynx, lung, stomach, liver, genitourinary 
tract) plasma Se concentration accounted for 99 ng/mL, whereas in the control group it was 
145 ng/mL (P < 0.001). The evaluation of 15 extensive surveys indicated that in 10 surveys 
(72 484 patients at the ESKD) the cancer risk (the observed number of cancers compared 
with the expected number) was 7.6 (Vamvakas et al., 1998). In the majority of cases, tumors 
of kidney, prostate, liver and uterus were recorded. Although the pathogenic mechanisms of 
the enhanced incidence of cancer in CKD patients have not as yet been elucidated, 
Vamvakas et al. (1998) suggest that the impaired function of the immune system, reduced 
antioxidant capacity together with the increased ROS generation involved in DNA molecule 
damage and depression of DNA are the most essential factors. The diminished DNA 
antioxidative defense of the body leads to an intensified attack of free radicals on DNA 
molecules and finally to the development of malignant diseases (Ames, 1989). ROS induce 
various kinds of damage in DNA, e.g. oxidative damage and DNA strand cleavage 
(Wiseman & Halliwell, 1996).  Hydroxyl radical reacts with DNA both with deoxyribose 
molecule, purine and pyrimidine bases (Fantel, 1996). The reaction of hydroxyl radicals with 
DNA results most frequently in damage to nitrogen bases, leading to the production of a 
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number of modified DNA bases, and finally to mutations. For example, 8-OH-guanine is a 
modified base. It may generate mutations contributing to a false reading of the modified 
base and its neighbouring bases. Transversion GC → AT is the most common change. Such 
a specificity of errors in 8-OH-guanine transcription plays a particular role in the mutation 
of gene that inhibits neoplastic changes (Fantel, 1996). Reactive oxygen species react both 
with nucleic and mitochondrial DNA (mtDNA). Human mtDNA is not shielded by 
histones, and thus it is easily damaged and the repair process is very slow (Shigenaga et al., 
1994).  
 
 
Fig. 10. Selenium concentration (left) and GSH-Px activity (right) in patients after kidney 
transplantation supplemented with 200 µg Se/day. Statistics: a, P < 0.0001 vs. controls; b, P 
< 0.01 vs. initial values; c (Se), P < 0.02 vs. placebo, and c (GSH-Px), P < 0.0001 vs. initial 
value; d, P < 0.01 vs. nonsupplemented group.  
Except for the findings on frequent development of cancer in CKD patients listed above, 
reports on DNA damage in this group of patients are scanty in the literature. Lim et al. 
www.intechopen.com
 Hemodialysis - Different Aspects 
 
88
(2000) investigated the frequency of mtDNA deletion in muscle sections taken from 22 CKD 
patients at the end-stage of the disease and in 22 healthy persons, free from any systemic 
diseases, matched by age and sex. Seventeen deletions (77%) were found in CKD patients 
and only five in the control group. These data show that mtDNA of skeletal muscles in CKD 
patients is extensively damaged and that these changes increase with age. Although the 
cause of DNA damage in CKD patients is still unknown, the authors (Lim et al., 2000) 
believe that accumulated uremic toxins, mostly of organic origin, are responsible for all the 
damage. These toxins stimulate ROS generation and damage cellular structures. ROS attack 
all structures, but mitochondrial genomes are thought to be most sensitive to the effect of 
free radicals. 
The commonly used biomarkers of oxidative stress include measurement of oxidative 
damage to DNA (cf. Zachara et al., 2011). They can be assessed by determination of 8-oxo-
7,8-dihydro-2′-deoxyguanosine (8-oxodG) level in cellular DNA and the determination of 
urinary excretion of oxidatively modified bases/nucleosides (Dziaman et al., 2009). Worthy 
of attention is the fact that over the past decade another method – the comet assay – has 
become one of the standard methods for assessing DNA damage and repair (Collins, 2009). 
Being free of artifacts, it is one of the most sensitive and accurate methods, and it is also a 
valuable tool in assessing the role of oxidative stress in human diseases, and in monitoring 
the effects of dietary antioxidants (Collins, 2009). For that reason, we used the comet assay 
method which reflects the DNA content in the comet tail as well as the length of comet tail 
(Hartmann et al., 2003). 
Nutrients constitute an important aspect of the antioxidant defense system with which 
humans have evolved (Ames, 2001). Selenium, as a nutrient, is the focus of this study and 
has, among others, two fundamental roles in cancer prevention: as a component of 
antioxidant defenses either as an agent able to scavenge free radicals or as an essential 
constituent of antioxidant enzymes such as GSH-Pxs (Combs, 1998; Schrauzer, 2003). 
Patients undergoing dialysis are at increased risk of many cancers, especially those of the 
kidney and urinary tract. Long periods of HD treatment are linked to DNA damage due to 
oxidative stress. In recent years, much attention has been paid to the role of selenium in the 
prevention of cancer of various organs (Valavanidis et. al., 2009; Reid et al., 2008; Gladyshev 
et al., 1998). Different forms of selenium compounds are administered to humans.  
We did not find research in which selenium would be administered to persons with CKD on 
hemodialysis. Therefore we checked the effect of selenium supplementation in the 
prevention/repair of damaged DNA in patients with CKD on maintenance hemodialysis 
(Zachara et al., 2011). Forty-two CKD patients treated with regular HD were studied in a 
randomized, double-blind, placebo-control trials. Selenium (yeast-Se) was supplemented to 
22 patients for 3 months with 200 µg Se/day, and placebo (beaker’s yeast) was administered 
to 20 patients. The patients were dialyzed three times a week for 4 hours. The results were 
compared between the groups and with 30 healthy volunteers. Blood was taken from 
patients before the study and after 1 and 3 months, while from healthy subjects blood was 
taken only once. Several different parameters were analyzed, but here I will focus  only on 
the results of DNA damage. DNA damage, including single-strand breaks (SSB) and alkali 
labile sites, were detected using alkaline single gel electrophoresis (SCGE; comet assay) 
according to the method of Singh et al. (1988) modified in our laboratory (Palus et al., 1999). 
The oxidative bases lesions in DNA were identified using formamidopyrimidine glycosylase 
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(FPG) enzyme which converts oxidized bases (Collins et al., 1997). The tail moment (tail 
length x tail % DNA/100) is the best indicator of DNA damage and will be presented here 
as the results achieved in the study.  
Plasma Se concentration in patients at the beginning of the study (both groups taken 
together) was 23% lower compared with the controls (40.6 ng/mL vs. 52.7 ng/mL, 
respectively; P < 0.0001). In Se supplemented group it increased after 1 and 3 months to 94.6 
and 115 ng/mL, respectively). In the placebo group there was no change in Se concentration 
throughout the study. Before the study the levels of single-strand breaks (expressed as the 
tail moment) were (in both groups taken together) before the study 3 times higher as 
compared with the control group (Fig. 11). 
    
 
Fig. 11. Single-strand breaks (SSB) of DNA in white blood cells of healthy subjects and CKD 
patients on HD supplemented with placebo (white columns) and Se-yeast (black columns): 
HD 0 = start of the study, month 0; HD 1 and HD 3 = after 1 and after 3 months of tablets 
supply. Statistics: a, HD 0 both subgroups vs. controls, P < 0.01; b, HD 1 +Se vs. HD 0 +Se, P 
< 0.02; c, HD 3 +Se vs. HD 0 +Se, P < 0.01.  
Almost the same values were obtained in relation to FPG: in patients they were 2.33 times 
higher than in the control group (Fig. 12). The higher, statistically significant levels of SSB 
and FPG in white blood cells of ESKD patients compared with healthy subjects at the 
beginning of the study shows that in those patients DNA is damaged, and that this may 
contribute to the development of cancer. The lower Se level in ESKD patients found in this 
study is probably responsible for DNA damage and may promote the development of 
cancer in such patients (Letavayova et al., 2006). Selenium supply in a dose of 200 µg/day 
led to the repair of damaged DNA. After 1 month the number of SSB was 2.4 times lower (P 
< 0.02) and after 3 months it was 4.3 times lower (P < 0.01). The FPG, after 3 months was 2.6 
times lower compared with HD 0.   
Epidemiological studies suggest that higher Se concentration reduces the risk of cancer 
(Letavayova et al., 2006) and increases DNA repair capacity in human fibroblasts damaged 
by H2O2 (Seo et al., 2002). Particular interest came from the clinical studies showing that 
dietary supply of organic Se, especially in the form of yeast enriched with Se, decreased the 
overall incidence of cancer twofold, above all of prostate, colorectal and lung cancers 
(Fisinin et al., 2009). 
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Fig. 12. Formamidopyrimidine glycosylase (FPG) in white blood cells of healthy subjects 
and CKD patients on HD supplied with placebo (white columns) and Se-yeast (black 
columns) at the beginning of the study (HD 0) and after 1 (HD 1) and 3 (HD 3)months. 
Statistics: a, HD 0, (both subgroups) vs. controls, P < 0.01; b, HD 3 +Se vs. HD 0 +Se, P < 
0.01; c, HD 3 +Se vs. –Se, P < 0.05. 
The data on the level of DNA damage in white blood cells of HD patients are in accord with 
the findings of Ribeiro et al. (2009) who have assessed the level of DNA damage by 
measuring the tail moment in various organs of Wistar rats in which the CKD was obtained 
by submitting the animals to 5/6 kidney mass ablation by ligation of kidney artery 
branches. The authors have also shown that CKD contributed to the damage of DNA not 
only in white blood cells but also in other tissues (liver, heart and kidney).  
Interesting results concerning the protective effect of Se against oxidative damage to  DNA 
in leukocytes of BRCA1 mutation carriers have recently been presented by Dziaman et 
al.(2009a). The authors demonstrated that BRCA1 deficiency contributes to 8-oxodG 
accumulation in cellular DNA  which,  in turn,  may be a factor responsible for cancer 
development in women with mutations, and that the risk to developed breast cancer in 
BRCA1 mutation carriers may be significantly reduced in Se supplemented  patients (300 
µg/day) (Dziaman et al., 2009b). 
The results of this study (Zachara et al., 2011) show that Se supplementation to HD patients 
reduced the level of DNA damage, as demonstrated by the progressive reduction of SSB and 
FPG in white blood cells. Longer term Se supplementation to patients on HD enhanced the 
protection of DNA against ROS, resulting in the reduction of the SSB and FPG levels. This 
dose (200 µg/day) and form (yeast enriched with Se) of the element was chosen because it 
had been shown that the inorganic form of Se is more toxic and less available than the 
organic form (Schrauzer, 2000). It is believed that the best form of Se for humans is the 
organic form – the selenomethionine (SeMet) (Schrauzer, 2001, 2003), and especially SeMet 
incorporated in yeast. It has been shown that SeMet enhances DNA repair and protects the 
cells against DNA damage (Laffon et al., 2010). Schrauzer (2009) has recently suggested that 
Se-yeast, in which the SeMet is protein-bound, shows a better effect than synthetic SeMet, 
since Se incorporated into protein is better protected from oxidation when exposed to air in 
the pure state. SeMet present in yeast is a protein-bound form, similar to the form normally 
present in food.  
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7. Conclusions 
Patients with CKD and especially those treated by dialysis are at increased risk of many 
diseases and among others cancers, especially those of the kidney and urinary tract. Long 
periods of HD treatment are linked to DNA damage due to oxidative stress. It has been 
shown that in white blood cells of HD patients some biomarkers of oxidative damage to 
DNA [8-hydroxy-2’-deoxyguanosine content of leukocytes (8-OH-dG), and DNA strand 
breakage (alkaline comet assay)] are higher than in healthy controls. 8-OH-dG has been 
shown to have mutagenic properties. Reactions of ROS with DNA, proteins, and membrane 
lipids have been demonstrated and they can lead to mutations, inactivation of proteins and 
disruptions of cell integrity. Supplementation of Se to these patients resulted, as shown in 
this study (Zachara et al., 2011), in a significant decrease in DNA damage. The benefits of Se 
supply might be either through the prevention or repair of DNA damage, and they 
implicate at least one selenoprotein – GSH-Px 1 – in the process.  
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